Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

As part of its quar­ter­ly clean­ing, Eli Lil­ly re­moved a few tri­als from its pipeline, in­clud­ing late-stage stud­ies of ap­proved can­cer drug Verzenio and its Boehringer In­gel­heim-part­nered drug Jar­diance.

The In­di­anapo­lis-based phar­ma gi­ant al­so re­moved a Phase 2 tri­al of a gene ther­a­py it got through the $1 bil­lion-plus ac­qui­si­tion of Pre­vail Ther­a­peu­tics a few years ago. Al­so out the door is an undis­closed Phase 1 im­munol­o­gy as­set, per the com­pa­ny’s first-quar­ter earn­ings pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER